BioPharma Dive - Latest News

GSK, Pfizer sales of RSV shots slow as vaccination rates ebb

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Feb 9, 2025 - 22:25
 0
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Read More

Tags:

Previous Article

Pfizer taps former Novartis exec to lead cancer drug push

Next Article

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Ve...

Related Posts

Sanofi to take $250M charge on study failure for E. Coli vaccine

Sanofi to take $250M charge on study failure for E. Col...

Feb 13, 2025  0

Stoke CEO exits; Medicare drug price talks advance

Stoke CEO exits; Medicare drug price talks advance

Mar 18, 2025  0

Bluebird, at risk of default, agrees to take-private deal

Bluebird, at risk of default, agrees to take-private deal

Feb 21, 2025  0